Onabotulinum Toxin A — Competitive Intelligence Brief

Onabotulinum Toxin A (Onabotulinum Toxin A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Ophthalmology.

marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Dermatology, Ophthalmology Small molecule

Target snapshot

Onabotulinum Toxin A (Onabotulinum Toxin A) — Walter Reed National Military Medical Center. Onabotulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Onabotulinum Toxin A TARGET	Onabotulinum Toxin A	Walter Reed National Military Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 50 UNT [Botox Cosmetic]	OnabotulinumtoxinA 50 UNT [Botox Cosmetic]	Amir Moradi MD, MBA	marketed	Botulinum toxin	SNARE complex (synaptosome-associated protein)
AbobotulinumtoxinA (ABO)	AbobotulinumtoxinA (ABO)	Hexsel Dermatology Clinic	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
incabotulinumtoxinA	incabotulinumtoxinA	Multiple Sclerosis Center of Northeastern New York	marketed	Botulinum toxin type A	SNARE complex (synaptobrevin/VAMP)
Clostridium Botulinum Toxin Type A	Clostridium Botulinum Toxin Type A	Daewoong Pharmaceutical Co. LTD.	marketed	Neurotoxin; botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
BOTULINUM TOXIN TYPE B	BOTULINUM TOXIN TYPE B	Eisai Co., Ltd.	marketed	Neurotoxin; botulinum toxin	Synaptobrevin (VAMP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

1. Galderma R&D · 2 drugs in this class
2. Hexsel Dermatology Clinic · 2 drugs in this class
3. Seoul National University Hospital · 2 drugs in this class
4. University of Utah · 2 drugs in this class
5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
6. EuBiologics Co.,Ltd · 1 drug in this class
7. Allergan · 1 drug in this class
8. GlaxoSmithKline · 1 drug in this class
9. Beth Israel Deaconess Medical Center · 1 drug in this class
10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class